2039-50-1

Basic information

• Product Name: 5-(Bromomethyl)-3-phenylisoxazole
• Synonyms: 5-(Bromomethyl)-3-phenylisoxazole;5-(Bromomethyl)-3-phenylisoxazole 97%;5-(Bromomethyl)-3-phenylisoxazole97%
• CAS NO: 2039-50-1
• Molecular Formula: C₁₀H₈BrNO
• Molecular Weight: 238.08062
• Mol File: 2039-50-1.mol
• Article Data: 18

Chemical Properties

• Melting Point: 82.5-85
• Boiling Point: 348.4°Cat760mmHg
• Flash Point: 164.5°C
• Appearance: /
• Density: 1.485g/cm³
• Vapor Pressure: 0.000102mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: 2-8°C
• PKA: -3.18±0.50(Predicted)
• CAS DataBase Reference: 5-(Bromomethyl)-3-phenylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(Bromomethyl)-3-phenylisoxazole(2039-50-1)
• EPA Substance Registry System: 5-(Bromomethyl)-3-phenylisoxazole(2039-50-1)

Safety Data

• Hazard Codes: C,Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 2039-50-1(Hazardous Substances Data)

Usage

General Description

"5-(Bromomethyl)-3-phenylisoxazole" is a versatile organic compound used as a chemical reagent or intermediate in various organic reactions, including pharmaceutical and chemical research. It is an isoxazole derivative, a class of organic compounds characterized by a five-membered ring structure consisting of three carbon atoms, one oxygen atom, and one nitrogen atom. Like other isoxazoles, this compound also exhibits unique chemical properties which gives it potential value in the creation of complex substances or drug synthesis. It must be used with care due to the bromomethyl group attached, which can cause it to be reactive, depending on the conditions. Its exact physiological and toxicological properties have not been thoroughly studied, thus it should be handled with appropriate safety measures.

InChI:InChI=1/C10H8BrNO/c11-7-9-6-10(12-13-9)8-4-2-1-3-5-8/h1-6H,7H2

Upstream product

• 873-67-6 benzonitrile oxide 
• 106-96-7 propargyl bromide 
• 513-31-5 2-bromoallyl bromide 
• 20141-73-5 benzaldehyde oxime O-tributylstannyl ether 
• 622-32-2 (Z)-benzaldehyde oxime 
• 100-52-7 benzaldehyde 
• 932-90-1 Benzaldoxime 
• 698-16-8 benzohydroximoyl chloride 
• 90924-12-2 3-phenyl-5-hydroxymethylisoxazole 
• 932-90-1 syn-benzaldehyde oxime 

Downstream Products

• 36895-31-5 3-phenyl-5-p-tolyloxymethyl-isoxazole 
• 62679-05-4 5-methylsulfanylmethyl-3-phenyl-isoxazole 
• 36895-33-7 N-[4-(3-phenyl-isoxazol-5-ylmethoxy)-phenyl]-acetamide 
• 1008-74-8 5-methyl-3-phenylisoxazole 
• 90924-12-2 3-phenyl-5-hydroxymethylisoxazole 
• 36821-71-3 N-(3-phenyl-isoxazol-5-ylmethoxy)-phthalimide 
• 36895-36-0 7-((3-phenylisoxazol-5-yl)methoxy)-4-methyl-2H-benzopyran-2-one 
• 36895-29-1 3-phenyl-5-o-tolyloxymethyl-isoxazole 
• 35121-45-0 5-naphthalen-2-yloxymethyl-3-phenyl-isoxazole 
• 35121-46-1 5-phenoxymethyl-3-phenyl-isoxazole 
• 103912-66-9 5-2-phenylamidino)aminomethyl>-3-phenyl-isoxazole 
• 1026-60-4 3-phenyl-5-piperidinomethylisoxazole 
• 1026-61-5 3-phenyl-5-morpholinomethylisoxazole 
• 1023-09-2 3-phenyl-5-diethylaminomethylisoxazole 

Relevant articles and documents

A metal-free approach for in situ regioselective synthesis of isoxazoles via 1,3 dipolar cycloaddition reaction of nitrile oxide with propargyl bromide

Herein, we report a multi-component reaction (MCRs) to synthesise a range of 3-phenyl-5-(bromomethyl)isoxazoles analogues using DMF/water mixture as solvent, providing desired products in good to excellent yields. The reaction efficiently involves the 1,3-dipolar cycloaddition reaction between propargyl bromide and in situ-generated α-chloro aldoximes. The protocol proceeded well under mild metal-free conditions and showed a tolerance for a wide range of substituents. Graphical abstract: [Figure not available: see fulltext.]

CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF

Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β -catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

Synthesis of Isoxazolines and Isoxazoles via Metal-Free Desulfitative Cyclization

A novel, one-pot reaction for the synthesis of isoxazolines and isoxazoles is developed via a cascade process under metal-free conditions. The approach involves the formation of intramolecular C-N and C-O bonds and intermolecular C-C bonds from aromatic alkenes or alkynes and N -hydroxysulfonamides using hypervalent iodine(VII) and iodine as the oxidant. Activation of C-H and C-C bonds/construction of C-O bonds/elimination of SO 2 /C-N bond formation is achieved in sequence in the reaction system.